3BDO

3BDO

Application

3BDO has been used to investigate the potential effects of metformin on inflammatory lung injury.

Biochem/physiol Actions

An orally bioavailable, brain-permeant suppressor of mTOR-mediated autophagy; reduces A? levels and prevents cognitive deficits in A?PP/PS1 mouse model.3-benzyl-5-[(2-nitrophenoxy) methyl]-dihydrofuran-2 (3H)-one (3BDO) blocks rise in LC3-II stimulated by uric acid (UA). It protects the capability of Rheb1-deficient macrophages to perform phagocytosis. 3BDO also prevents the inhibitory effects of EX-527 on eukaryotic translation initiation factor-binding protein 1(4E-BP1) phosphorylation.

3BDO is a cell-permeable, orally bioavailable, non-toxic butyrolactone derivative that is shown to competitively bind FKBP1A (FK506-binding protein 1A, 12 kDa) in a reversible manner, and suppress autophagy via the mTOR pathway. 3BDO inhibits both LPS- and oxLDL-induced autophagy in HUVECs, increases TIA1 phosphorylation, and reduces autophagosomes number. It is reported to be brain permeant, and significantly decreases atherosclerosis development in apoE-/-?mice (100 mg/kg, q.d., p.o.). 3BDO increases IDE and neprilysin levels, lowers amyloid-β deposition in an AβPP/PS1 transgenic mouse model of Alzheimer′s disease, and alleviates memory deficits.

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level Manufacturer Storage Temp. Form Assay Price Quantity
3575268 3BDO colorless to light brown 100 SIGMA-ALDRICH 2-8°C
£530.68 (exc VAT) per 25MG
-
+
3575269 3BDO colorless to light brown 100 SIGMA-ALDRICH 2-8°C
£164.36 (exc VAT) per 5MG
-
+